Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
NEWS! Hoth Therapeutics Executes Licensing Agreement of VNLG-152 for Treatment of Dermatological Diseases
Hoth to receive equity stake in Isoprene, full license of VNLG-152 and royalties from Isoprene for all other fields including Oncology
NEW YORK, July 31, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it has executed a licensing agreement with Isoprene Pharmaceuticals, Inc. to acquire the rights to VNLG-152, a novel retinamides (Retinoic acid metabolism blocking agents, or RAMBAs) for the treatment of dermatological diseases. Isoprene is a cancer therapeutic company that is a University of Maryland, Baltimore New Venture Initiative start-up.
This agreement, which formalizes the previously announced Letter of Intent between the two companies, will also grant Hoth royalty payments from Isoprene for any use of its VNLG-152 including Oncology.
Researchers at the University of Maryland Baltimore discovered novel retinamide RAMBAs and validated their therapeutic utility in animal models of breast and prostate cancer. RAMBAs inhibit the cellular enzyme that metabolizes all-trans retinoic acid (ATRA), which actively directs cells to mature in a controlled manner to ensure normal growth.
In addition to enhancing the beneficial effects of ATRA, the mechanism of action for these RAMBAs has been shown to involve degradation of Mnk 1/2 and suppression of the oncogenic eIF4E pathway. For potential use in treating dermatological conditions, UMB researchers obtained promising early results demonstrating that lead retinamide RAMBAs have equal or superior effects over approved retinoids (ATRA and 13-CRA) to inhibit proliferation of normal human adult keratinocytes and sebocytes, and antikeratinizing effects in reconstructed human epidermis. Initial toxicity profiles for a panel of RAMBAs [Njar et al., 2006] also showed good indications for safe therapeutic use.
These novel RAMBAs block the normal metabolism of endogenous ATRA in cells, increasing the beneficial effects of ATRA. They provide a unique approach to achieve the therapeutic benefit of retinoid therapy while potentially circumventing the adverse events associated with it, a very important property for application to dermatology therapy. ATRA deficiencies are associated with dermatological diseases (acne and psoriasis), and retinoid derivatives have been one of the mainstay therapies for acne. Liarozole is in clinical use for the treatment of psoriasis and ichthyosis. Dermatological retinoid deficiencies are characterized by hyperkeratinization and desquamation and include diseases such as acne, eczema, psoriasis, cold sores, wounds, burns, sunburn, ichthyosis, skin cancer, and Kaposi's Sarcoma, all of which are plausible targets for retinamide RAMBA therapy.
Mr. Robb Knie, Chief Executive Officer of Hoth, commented, "Hoth is pleased to finalize this licensing agreement of a novel therapy that has shown such promise in targeting such a wide array of dermatological afflictions. This latest license agreement reinforces Hoth's commitment to developing novel therapies for multiple skin diseases."
About Hoth Therapeutics, Inc.
Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. Hoth's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. Hoth has also recently entered into two different agreements to further the development of two different vaccine prospects to prevent or treat COVID-19. To learn more, please visit www.hoththerapeutics.com.
Hopefully an up day tomorrow?
We should be hearing a follow up update from the following news/pr! IMO. https://www.otcmarkets.com/stock/AIKI/news/story?e&id=1641643
Its means dilution for a quick cash infusion
Offerings not always bad, correct? Or too risky to hold through one?
The chart its below the 50 ma....Which means it cant hold gains...An offering must be coming
what do you not like about this penny? Thanks in advance.
should have listened...
TrendTrade2016 Monday, 07/20/20 05:15:21 AM
Re: None 0
Post #
7916
of 7995
AIKI IS GARBAGE STAY AWAY!!
Longterm is its barely above the 50ma
$AIKI Alkido Pharma Inc (AIKI)
1.21 ? -0.01 (-0.82%)
Volume: 7,076,592 @07/24/20 7:59:16 PM EDT
Bid Ask Day's Range
1.18 1.2 1.13 - 1.32
AIKI Detailed Quote
http://schrts.co/SNZySEMg
Added some today, didn't get the low tho.
Look at the close and don’t post weired charting. Better check longterm trend
More downtrend on the intraday look at the trend
How many more?
$1.24 seems cheap today. This is preparing for a huge move up it looks like!
This things seems ready to Explode!!!
GLTA
And whut do we have here
Nice huh!
AIKI up she goes $1.32 after hours.
AIKI...$1.23...Hit $1.28 Hod off the $1.12 bounce...
georgie18 Tuesday, 07/21/20 09:53:06 AM
Re: None 0
Post #
7962
of 7976
AIKI...$1.12...Dip filled the open gap this morning...should move hard from here...imo...we shall see...
Off to the Races
Push the button
Up 12% to $1.20 so far. Hopefully it continues going up!
Buy Technicals is back! https://www.tradingview.com/symbols/NASDAQ-AIKI/technicals/
If someone paid 3 dollar, why not paying 1 dollar for that stock?!?
Wait for it lol..
AIKI consolidation time it looks like before the big take off?
For making IDIOTS making market here to buy High and sell Low, I deserve some BIG APPLAUSE. Some please APPLAUD ME!
Ding ding ding you my sir are wrong!!
Followers
|
156
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
8287
|
Created
|
12/30/04
|
Type
|
Free
|
Moderators |
Kucera Paper Lipid Nucleoside Conjugates for the Treatment of Cancer
Kucers & Pardee Paper Improving Nucleoside Analogs via Lipid Conjugation
The Phospholipid Gemcitabine Conjugate, KPC34, is a Novel Treatment for Leukemia
Short-term Toxicity Study of DHA-dFdC
AIkido Pharma Inc. seeks to enhance shareholder value not only through exceptional business performance and practices,
but also through responsible and effective communication with its shareholders. The latest company information relevant to the individual
and institutional investor includes stock price and history, upcoming events and presentations and financial documents.
AIkido Pharma Inc. is traded on the Nasdaq under the ticker symbol AIKI.
AIkido Pharma Inc. is a biotechnology development company with a diverse portfolio of early stage small-molecule anti-cancer therapeutics.
The Spherix platform contains patented technology from leading universities and researchers and we seek to develop
our innovative drugs through strong partnership with world renowned institutions, such as The University of Texas and Wake Forest University.
Our diverse pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL).
Our pancreatic treatment has shown positive preclinical results for inhibiting pancreatic tumor growth in clinically relevant transgenic mouse models.
The drug has also demonstrated the potential to overcome tumor cell resistance to current chemotherapeutic drugs.
Our AML drug is a next generation targeted therapeutic designed to overcome multiple resistance mechanisms observed with the current standard of care.
In addition, we are constantly seeking to grow our pipe to treat unmet medical needs in oncology.
https://ir.aikidopharma.com/stock-information/
$AIKI Spherix Incorporated, a biotechnology company,focuses on developing small-molecule anti-cancer therapeutics.
Its pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia.
The company's platform consists of patented technology from leading universities and researchers and in the process of developing an
innovative therapeutic drug platform through partnerships with world renowned educational institutions, including The University of Texas at
Austin and Wake Forest University.
It has a scientific research agreement with The University of Texas Southwestern Medical Center to use machine learning to find genetic
markers in people that indicate an increased risk of developing pancreatic cancer.
Spherix Incorporated was founded in 1967 and is based in New York, New York.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |